<DOC>
	<DOCNO>NCT02786134</DOCNO>
	<brief_summary>Coronary flow reserve ( CFR , calculate ratio hyperemic rest myocardial blood flow ) emerge powerful quantitative prognostic imaging marker clinical cardiovascular risk . CFR provide robust reproducible clinical measure integrate hemodynamic effect epicardial coronary artery disease ( CAD ) , diffuse atherosclerosis , microvascular dysfunction myocardial tissue perfusion . Inflammation key mediator constellation abnormality , affect entire coronary vasculature , clinical trial date show directly reduce inflammation lower cardiovascular event rate . As , recently launch Cardiovascular Inflammation Reduction Trial ( CIRT ) provide unique opportunity mechanistic investigation impact anti-inflammatory therapy change CFR reflection coronary vascular dysfunction , may precede clinical outcome , particularly patient high-risk event . The investigator ideally position examine impact inflammation CFR , extensive experience quantitation CFR use clinically-integrated dynamic positron emission tomography ( PET ) ability ass association cardiovascular outcome . The central hypothesis ancillary proposal , CIRT-CFR , reduce systemic inflammation use low-dose methotrexate ( LDM ) , compare placebo , quantitatively improve myocardial blood flow coronary flow reserve measure PET one year , stable CAD patient type 2 diabetes metabolic syndrome enrol CIRT . In , improvement coronary vasoreactivity , endothelial function , tissue perfusion may beneficial effect myocardial mechanic , leave ventricular deformation function , ultimately , symptom prognosis .</brief_summary>
	<brief_title>Coronary Flow Reserve Assess Cardiovascular Inflammation ( CIRT-CFR )</brief_title>
	<detailed_description>Randomization double-blind study treatment period either placebo LDM ( 1:1 ) willing eligible patient occur end open label run-in phase per parent CIRT protocol , stratify time since qualify event ( &lt; 6 ≥ 6 month date MI recent angiogram ) , type event ( MI multivessel CAD ) , presence either type 2 DM metabolic syndrome , site , ensure balance propose study . Patients willing participate CIRT ask enroll sub-study may sign CIRT-CFR informed consent point sign parent CIRT inform consent complete parent CIRT randomization visit ( Visit 4 ) . After give informed consent ancillary CIRT-CFR , patient undergo baseline PET scan along echocardiography point parent CIRT post run-in visit ( Visit 3 ) 4 week randomization ( Visit 4 ) . Imaging perform 3 imaging center ( BWH , OHI , UAB ) . To minimize participant site burden , baseline single follow-up imaging time point pursue . Imaging test ( PET echo ) schedule day patient convenience possible , one week apart . `` Baseline '' study visit image follow open label run-in period parent trial enhance long-term compliance eliminate risk radiation exposure individual immediate intolerance LDM study protocol . The imaging test propose non-invasive , routinely perform , historically well tolerated patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1 . Age ≥18 year screen ; 2 . Documented past history MI OR past evidence multivessel CAD angiography , complete plan coronary revascularization associate qualify event least 60 day prior enrollment , clinically stable ≥60 day prior enrollment ; qualify prior MI must document either hospital record , evidence current ECG Q wave 2 contiguous lead , and/or image test demonstrate wall motion abnormality scar ; qualify evidence multivessel CAD angiography must document CAD least two major epicardial vessel define either presence stent , coronary artery bypass graft , angiographic lesion 60 % great ( left main CAD revascularized stent bypass graft qualify multivessel disease , presence 50 % great isolated leave main stenosis ) ; 3 . History type 2 DM metabolic syndrome ( meeting 2004 AHA/NHLBI definition* ) time study enrollment ; *includes 3 follow 5 diagnostic criterion : waist circumference ≥ 102 cm men 88 cm woman ; triglyceride ≥ 150 mg/dl drug treatment elevate triglyceride ; highdensity lipoprotein cholesterol ( HDLC ) &lt; 40 mg/dL men &lt; 50 mg/dL woman drug treatment reduce HDLC ; systolic blood pressure ≥ 130 mm Hg diastolic blood pressure ≥ 85 mm Hg drug treatment hypertension ; elevate fast glucose ≥ 100 mg/dL drug treatment elevate glucose . 4 . Willingness participate evidence sign CIRT CIRTCFR inform consent . Exclusion criterion : 1 . Prior history chronic infectious disease , tuberculosis , severe fungal disease ; chronic hepatitis B C infection ; renal insufficiency ; interstitial pneumonitis , bronchiectasis , pulmonary fibrosis ; know chronic pericardial effusion , pleural effusion , ascites ; chronic liver disease ; myeloproliferative disorder past 5 year ; nonbasal cell malignancy treat lymphoproliferative disease within past 5 year ; know HIV positive ; life expectancy &lt; 3 year ; 2 . Chronic inflammatory condition lupus rheumatoid arthritis , ulcerative colitis Crohn 's disease 3 . White blood cell count &lt; 3,500/ul , hematocrit &lt; 32 percent , platelet count &lt; 75,000/ul 4 . Liver transaminase level ( AST ALT ) &gt; upper limit normal ( ULN ) albumin &lt; low limit normal ( LLN ) ; 5 . Creatinine clearance &lt; 40 ml/min estimate CockroftGault equation ; 6 . History alcohol abuse unwillingness limit alcohol consumption le 4 drink per week 7 . Women child bear potential , even currently use contraception , woman intend breastfeed . 8 . Men plan father child study period unwilling use effective form contraception . 9 . Requirement use drug alter folate metabolism ( trimethoprim/sulfamethoxazol ) reduce tubular excretion ( probenecid ) know allergy antibiotic make avoidance trimethoprim impossible ; 10 . Current indication methotrexate therapy ; 11 . Chronic use oral steroid therapy immunosuppressive biologic response modifier ( see Exclusionary Medication List Manual Operations ) . Eligible study participant encourage date pneumococcal influenza vaccination recommend base age underlie medical condition . 12 . Chest Xray evidence past 12 month interstitial pneumonitis , bronchiectasis , pulmonary fibrosis . For participant chest Xray prior 12 month , chest Xray obtain baseline part study protocol . 13 . New York Heart Association Class IV congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>